Purpose. To analyze the challenge of using health outcomes data to compare plans, networks and providers.
The challenges of using health outcomes data to compare admission may have received such poor care that their illness plans, networks and providers are often overlooked. To set went un-noticed or untreated. the stage for this special edition of the International Journal for By definition, health outcomes data relate to a prior Quality in Health Care, this paper first considers use of health intervention. We use the outcomes data to infer if an interoutcomes data collected in different research designs. This vention caused the state of health that we observe in a group review leads to a discussion concerning uses of either process of persons. or health outcomes data for comparing plans, networks and Figure 1 represents outcomes data for three groups of providers.
persons: A, B and C. Our discussion is not limited to data samples of nine persons, however: nine circles are simply convenient for the diagram. The persons represented in this diagram are not selected by any clinical condition. Any type
Interpreting health outcomes data
of outcome measure is shown here: we can imagine many possibilities, from clinical test results to patient-reported In his classic paradigm of structure, process and outcome health status measures. [1] , Donabedian uses the phrase 'health outcomes' to refer On observing the persons in Figure 1 after some prior to measures of the health of patients, specifically observations intervention, we can only say that they are now different in of events within a persons body and mind. Health outcomes their health. They may also have been different before the do not include events such as admissions or readmissions:
intervention, implying that the intervention had no effect. these events are processes of care that can be used as proxy Or, if these differences in health relate to a prior intervention, measures of worse health. However, finding persons who it may not be the intervention that we have in mind, but were readmitted does not necessarily find all whose health deteriorated. Some people who became ill enough to justify some other intervention that we may not have considered. What do these data tell us? For group A, the time 2 people per group.
are less sick, and for group B the time 2 people are more sick. For group C, there is no difference in how sick the people are at time 1 and time 2. If these data came from three plans, what could we deduce? Perhaps a group of well people joined plan A between time 1 and time 2. Perhaps a group of sick people joined plan B between time 1 and time 2. We cannot tell which explanation is correct.
If the enrollment populations were stable in all three plans, the data could reflect simply the natural history of health and disease in people who happen to belong to three different plans. Maybe plan A had many enrollees in time 1 with shortlived illnesses who were destined to get better. Perhaps some very sick people in plan A died between time 1 and time 2 and so were not sampled in time 2. Maybe plan B had many people in time 1 who had illnesses that we would expect to get worse by time 2. Perhaps some significant environmental event hit enrollees in plan B just before time 2, such as a flu Figure 2 Interpreting outcomes data: time series. Data from epidemic, and this epidemic didn't affect enrollees in plans two points in time, time 1 and time 2. (See Figure 1 for A and C. explanation of symbols.)
We could address these questions better by stratifying the data by diagnosis or clinical condition. This design would account at least for one source of variability in the natural Now suppose that groups A, B, and C in Figure 1 represent persons who had enrolled earlier in three different health history of their health. We can also distinguish causes and effects better if we collect these time series data prospectively plans. Did plan A attract sicker people than plans B and C? Or did plan A draw its patients from a location where there for the same persons at two points in time -a cohort study -as illustrated in Figure 3 . In Figure 3 we can see that two are lots of sick people? Or did plan A give inadequate or incompetent care so that its patients became sicker than persons labeled A1 and A2 stayed sick whereas A3 got much better. Person B3 got much worse. those in plans B and C? We cannot answer these questions from this study design.
However, with this design we lose sight of persons who died between time 1 and time 2 (perhaps because they got Figure 2 illustrates a more sophisticated design, with data for groups A, B, and C collected at two points in time. The bad care) or who left the plan between time 1 and time 2 because they believed that they got bad care. two measurements do not necessarily come from the same persons: fresh samples of persons were drawn from each If we select the persons in Figure 3 by diagnosis we can improve our ability to distinguish effects caused by the time group at time 1 and time 2.
course of different illnesses further. For instance, if all these persons had a heart attack at time 1, we might choose to set time 1 and time 2 at 2 years apart in order to observe the effects of the care given. However, for persons with high blood pressure, who are treated in order to prevent complications such as stroke, heart attack and kidney disease that can occur many years later, we must set time 1 and time 2 many years apart. We will undervalue the care given if we observe hypertension outcomes at 2 years.
Health promotion and disease prevention are also undervalued by short term outcome measurements -'I will not feel any better or appear any better today on any outcome measure if my provider gives me a pneumonia vaccination today, or provides a mammogram today, or persuades me to start eating less fat today, but these interventions may save my life some time from now'. Figure 4 Comparing treatments: quasi-experimental studies. Selecting or stratifying groups by diagnosis requires con-Data collected for persons who were grouped by the treatment firmation that diagnoses were correctly made. Suppose we they happened to receive, either treatment A, treatment B or selected patients with a diagnosis of heart attack for outcomes no treatment. Time 1 measurements were made before comparison. What if providers in plan A often over-diagnose treatment status was determined and time 2 measurements heart attacks ? We might include in plan A, as heart attack after treatment status was determined. (See Figure 1 for victims, patients A3, A4 and A8 who only had heart burn -explanation of symbols.) of course they will be less likely to have angina or heart failure by time 2. On the other hand, if plan A providers under-diagnose heart attacks, they may send patients with so that persons with low incomes might be attracted to them. heart attack home from the emergency room. These un-However, these persons might not be able to buy the effective fortunate people may die without our knowing it because treatment with their own money. We need to distinguish they would not to be surveyed at time 2.
between these explanations of differences in health outcomes Another way to disentangle the effects of the provider among the three plans in order to decide how to improve from all other effects in time series comparisons is to adjust care. the time 2 data for the risk of a bad outcome associated with If we look only at outcomes data, we cannot tell whether the health status of individuals at time 1. If we could 'adjust' an effective treatment exists, whether it was offered to for diagnosis, severity of illness, co-morbidity and other risk patients, and if offered, whether patients took the treatment. factors that affect the outcome, we level the odds of showing How can we separate these causes and effects? To answer improved outcomes for all three plans. We can discern more this question we must consider methods to determine the easily any differences between the groups in their outcomes, effectiveness of treatments. and so make fairer comparisons.
To determine whether a treatment accounts for differences With comparisons adjusted for risk factors, we can better in outcomes for individuals with a particular disease, we need determine which plan's patients got better or worse, relative a radical revision of the study design: Figure 4 illustrates such to the health status they could expect at time 2. For instance, a design. Instead of collecting health outcomes data on people we might find, after adjustment or stratification, that the who belong to different plans, we collect data on people difference in outcomes among these plans shown in Figure who did or did not receive treatment, irrespective of their 3 disappears. However, risk adjustment would not help to enrollment in any plan. explain why all plans got the same results. It could be Many patient outcomes research teams use the quasithat all plans give effective care in equivalent amounts. experimental design illustrated in Figure 4 . Notice that the Alternatively, it could be that there is no treatment for this patients in treatment groups A and B, those persons whose particular disease so that no provider could have altered the providers decided to offer them treatment, are mostly sicker course of health for these patients. It could also be that the than those in group C who were not offered treatment. We effective treatment is complicated to follow and so patients can only begin to interpret these data inasmuch as we can in all plans tend to drop out of treatment.
control for patient variables, other than treatment, that affect Similarly, if plan A got better results than plans B and C, outcome. we still would not know why. Suppose there is a new and Researchers who classify study designs grade this type of effective treatment. Maybe the providers in plan A kept up study as producing weak evidence. For instance, the US to date and so offered this treatment whereas the providers Preventive Services Taskforce used in its deliberations a fivein plans B and C were not aware that an effective treatment level hierarchy for strength of evidence. Expert opinion gets existed. Maybe the effective treatment is very expensive and the lowest value for strength of evidence. Uncontrolled plans B and C refuse to pay for it. By refusing to pay for time series produce slightly stronger evidence. Still greater credibility attaches to well-conducted case-control and cohort drugs, plans B and C might be able to offer lower premiums Figure 5 Comparing treatments: randomized controlled trials. Figure 6 Comparing plans, providers and networks using Data collected for persons who were randomly assigned to outcomes data. Data collected for persons grouped by their groups, with groups then randomly assigned to treatment receipt of care from either plan A, B or C, with measurements protocols, treatment protocol A, treatment protocol B or made before and after receiving care from the plan for a no treatment. Outcomes measurements were made using standardized interval of time. (See Figure 1 for explanation standardized instruments at standardized intervals before and of symbols.) after treatment/no treatment with both providers and patients blinded to treatment status. (See Figure 1 for explanation of often see tables of health outcomes data comparing results symbols.)
at time 1 and time 2. It is easy to forget all the special conditions that constrained the collection of these data if they came from an RCT. If you forget that, you can mistakenly studies, then to controlled studies without randomization. The strongest evidence of cause and effect comes from believe that you have strong evidence when you see tables of health outcomes data that were not collected under these randomized controlled trials [2] . Figure 5 illustrates a randomized controlled trial (RCT). strict experimental conditions. And, of course, we usually do not have strict experimental conditions when we are comThe strongest evidence to evaluate a treatment comes from collecting outcomes data in a double blind RCT [3] . This paring plans as opposed to treatments. Figure 6 illustrates how easy it is to slide into this kind of mistake. design overcomes the problems of interpretation that we examined above. In Figure 5 , groups A, B and C represent
The data format in Figure 6 looks just like the format in Figure 5 ; however, in Figure 6 , persons in groups A, B and persons who have the same disease and are similar in severity and co-morbidities. We assign these persons to each group C are not randomly assigned to their group, and groups are not randomly assigned to treatments. Instead, Figure 6 shows using random number tables. This usually creates groups with exactly the same mix of patients, even for those patient persons who selected themselves to enroll in different plans and who differ in severity of illness. differences that we overlooked or cannot measure. We assign the three groups by random number tables to treatments Even if we selected these individuals by diagnosis, we could not confirm the diagnosis because that is decided by that are given according to strict protocol. We blind both providers and patients as to the group that each patient is the physician who saw the patient. These individuals are not receiving treatment according to a strict protocol, but as they in. We measure health outcomes using standard instruments at standard times relative to treatment. We include adequate and their physician decide. Any outcome measurements made may occur at erratic intervals in non-standardized notations numbers of individuals to allow for the effects of chance.
With this design, if differences are statistically significant made by a variety of health care practitioners. Still more troubling, the health care practitioners making outcome measor exceed the confidence intervals, we believe them strongly. From the data in Figure 5 , for instance, we would conclude urements are not blinded to treatment. Even if standard outcomes measurement instruments are used for plan comthat treatment A works well, and that treatment B works less well.
parisons, such as patient health status surveys, and even if these are administered at standard time intervals, the patients This design yields credible results, but of course we cannot apply it in comparisons of plans. When we compare plans themselves are not blinded to treatment. The numbers of individuals within a plan, particularly if we stratify by diagnosis, for quality improvement purposes we cannot randomize persons to plans. With this and every other departure from may not make up an adequate sample size to exclude chance effects. the double blind RCT format, the strength of our causal inference linking providers to health outcomes falls.
This design doesn't yield strong evidence; in fact, without careful interpretation the data can actually be misleading. For People concerned with health care are used to seeing data from RCTs and believing the results. Physicians, particularly, instance, what if plan B is giving much better care than plans
Clarifying the questions
The discussion above leads us to this conclusion: we should clarify the question we are asking before we design our outcomes data collection.
When our purpose is evaluating effectiveness of treatments or screening tests or other technologies, we are asking what processes improve health outcomes? For this question, the strongest evidence comes from a double-blind randomized controlled trial. To overcome the rigidities of this design, we may prefer quasi-experimental or epidemiological studies. Nevertheless, throughout the study we employ methods to isolate the effect of the treatment or technology, and suppress effects attributable to plans, networks or providers.
In program evaluations, we are asking what is the impact Figure 7 Comparing plans, providers and networks using of this policy and related programs on health outcomes? For process data. Health status data from one point in time, this purpose, we may be able to randomize subjects, but are collected to determine those persons who required a specific more likely to have a quasi-experimental or an epidemiological treatment. These persons were grouped by their receipt of design. In every aspect of study design we try to isolate the care from either plan A, B or C. The treatment data reflect effect of the program from effects attributable to specific the percentage of persons in each group who received the plans, networks or providers. required treatment. (See Figure 1 for explanation of symbols.)
However, when we make provider comparisons our goal in study design is the exact opposite because we are asking quite different questions. Do these specific providers perform differently from one another? Do these specific providers perform satisfactorily compared with some absolute standard? A and C in both time 1 and time 2? Perhaps, because it is Are these specific providers improving their performance over giving such good care at time 1, large numbers of sick people time? Instead of removing the effects attributable to specific rush to join it: by time 2, plan B will look worse -but is it plans and providers and studying plans and providers in because sick people joined it, or because it gave such bad general, we want to isolate for study the effects attributable care that mildly ill people deteriorated and became sick?
to specific plans. For these questions, comparisons of proThe difficulties of making sound interpretations of data cesses of care are often easier to interpret and more sensitive derived from outcomes comparisons make an alternative to small differences than outcomes data comparisons. approach attractive -namely, using process data for plan Whether we use process or outcome data, however, in order comparisons. If we already have strong evidence from prior to make fair comparisons, we must ensure that the data research, showing that certain patients will improve in health collected from the different plans are from similar samples if given a certain treatment, we need not repeat that research of patients and that the data collected about each patient in the less controlled situation of plans giving routine care. conforms to standardized definitions. We can simply ask how plans compare on giving the effective treatment for this type of person. Figure 7 illustrates this type of design: instead of a prospective study collecting Using process data for comparisons outcomes data over time, we can do a retrospective study of the prior year using process of care data.
In plan comparisons, when should we prefer process to This design has major advantages when our purpose is outcomes data? We can use process data whenever we have stimulating quality improvement or guiding purchases. It is strong evidence or beliefs that particular processes affect relatively inexpensive to collect data, gives quick results, and important outcomes. Process data are especially useful for is more sensitive to small differences between plans than an comparisons when one or more of the following apply: outcome study [4] . We can also use the design to compare plans on performance of tests that are shown, by scientific • the goal is improving delivery of care; evidence, to improve health outcomes, such as screening • we need to know why specific providers achieve particular tests.
outcomes; In some circumstances, process comparisons may be valu-• short time frames are necessary; able even if we don't have strong scientific evidence [2] .
• the processes of interest affect long-term outcomes; Consider an airplane that crashes because a substantial number • performance of individual providers is of interest; of bolts are missing from the airplanes wing. No-one has • performance of low volume providers is of interest; conducted an RCT to test whether omitting bolts from • tools to adjust or stratify for patient factors are lacking; airplane wings causes planes to crash, but most of us would • providers are being compared in a competitive/coercive situation. not fly in a plane that we knew had missing wing bolts.
If we are responsible for improving care, we must eventually • long time frames are possible;
• performance of whole systems is of interest; get data on the processes of care, because the only way we can improve patients outcomes is by improving what we do • performance of high volume providers is of interest;
• comparing providers in a cooperative situation. for them.
If we compare providers on outcomes to identify those Suppose we want to prioritize areas for quality imwith the worst outcomes, then we must study their processes provement, and have evidence about the processes of care of care to see how they might improve. What are they doing that improve outcomes for a clinical condition, and know or not doing that makes their results worse? However, even how good the outcomes should be if that care were given if we find all providers have similar outcomes we will still well. In this situation, outcome comparisons help us to detect need to study processes. What if they have similar outcomes whether the outcomes achieved are less good than they because they are all falling short in giving effective treatments should be. This may be the best way to uncover mistakes to appropriate patients? The Medicare program encountered and oversights in implementing care. Finding error-prone this situation in the Cooperative Cardiovascular Disease areas of care falls into the category that John Williamson Program [5] . The study reported data on use of processes of calls 'achievable benefit not achieved' [6] . When outcomes care shown by strong evidence to reduce deaths from heart fall short of the level known to be possible, we have found a attacks, namely thrombolytics, beta blockers and aspirin. All good place to spend limited resources for quality management of the study hospitals could have achieved better outcomes because there are opportunities for big improvements. than they did: they failed to use these treatments for all Outcomes comparisons are particularly useful when we patients without contraindications to treatment.
can wait to observe long-term outcomes, and are interested Process data are useful when we need results of com-in the impact of whole systems or programs of care on the parisons in a short time frame, and when the processes affect health of large populations. When we compare large volume important long-term outcomes. Process data are the best way providers, we can obtain sufficient sample sizes to detect to compare provider groups or individual providers who differences in outcomes. contribute only the part of the care received by a patient. In
Because the strength of evidence in non-experimental this common circumstance, when we look at outcomes only, comparisons is weak, outcome comparisons are most useful we cannot tell which providers to credit for a good outcome, when working with providers in a voluntary and cooperative or if all should share the credit.
mode. Using outcome comparisons in coercive and comIf the provider groups under comparison have small num-petitive situations, where each provider has high stakes in bers of cases eligible for study, outcomes studies are not the result, can encourage gaming that produces perverse possible, because detecting differences in outcomes requires effects. For instance, providers may avoid enrolling sicker large sample sizes [4] . patients. By avoiding sicker patients, providers can achieve If we lack methods to adjust for differing risks for a bad better outcomes [7] . Better outcomes can also result if risky outcome, process comparisons are more interpretable than procedures are withheld from higher risk patients [8] . Plans outcome comparisons, although process comparisons, too, can appear to improve outcomes if sicker patients disenroll: are sharpened by adjustments or stratification on relevant just raising the barriers to care may be enough to persuade patient factors. sick persons to go elsewhere [9] . Up-coding diagnoses and Outcome studies are especially problematic when we are documentation of patient factors that are known to be used using comparisons for coercive or competitive purposes. to adjust outcomes data can also mimic real improvement in Providers in these situations have a big stake in the action outcomes [10] . Of course, improving accuracy of coding is that follows from the results. They may contest the findings desirable, but exaggerating the nature of the patients illness or start gaming to evade them. If we have used a weak study when selecting disease coding is not. design, the contest over interpretation of data can go on virtually forever. Gaming to ensure better-looking health outcomes data can produce negative effects for patients.
Conclusion
Using health outcomes data to compare plans, networks and Using outcomes data for comparisons providers poses many challenges that are often overlooked. In reviewing these challenges the following points emerge. In plan comparisons, when should we prefer outcomes to
• In interpreting health outcomes data, we must clarify process data? We can use outcomes data whenever we have the question we are asking. Different questions require tools to adjust or stratify for patient factors that affect the different designs for collecting and interpreting the outhealth outcome. Outcomes data are especially useful for comes data; comparisons when one or more of the following apply:
• Designs that yield strong evidence, and that are typically used in evaluating treatments, cannot be applied when • we seek areas for quality improvement;
• specific processes are known to yield specific gains in comparing plans, networks and providers for purposes of quality improvement. outcomes;
• safe implementation of processes is of interest;
• When we have good evidence linking specific processes
